{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,24]],"date-time":"2026-01-24T17:04:36Z","timestamp":1769274276869,"version":"3.49.0"},"reference-count":37,"publisher":"Wiley","issue":"1","license":[{"start":{"date-parts":[[2025,2,12]],"date-time":"2025-02-12T00:00:00Z","timestamp":1739318400000},"content-version":"vor","delay-in-days":11,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100000925","name":"National Health and Medical Research Council","doi-asserted-by":"publisher","award":["1136923"],"award-info":[{"award-number":["1136923"]}],"id":[{"id":"10.13039\/501100000925","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["eJHaem"],"published-print":{"date-parts":[[2025,2]]},"abstract":"<jats:title>ABSTRACT<\/jats:title><jats:sec><jats:title>Background<\/jats:title><jats:p>The TROG 99.03 trial demonstrated improved progression\u2010free survival for patients with early\u2010stage follicular lymphoma (FL) treated with systemic therapy using rituximab\u2010cyclophosphamide, vincristine, prednisolone (R\u2010CVP) after involved\u2010field radiotherapy (RT) versus RT. As systemic therapy was associated with more acute toxicity, the possibility of long\u2010term toxicity, and no survival benefit yet, the cost\u2010effectiveness of RT+R\u2010CVP is important.<\/jats:p><\/jats:sec><jats:sec><jats:title>Aim<\/jats:title><jats:p>We performed a cost\u2010effectiveness analysis of RT (reference), RT+CVP, and RT+R\u2010CVP from the TROG 99.03 trial.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>We constructed a Markov model (15\u2010year horizon) to compare treatments: RT (reference), RT+CVP and RT+R\u2010CVP from the 150 patients in the TROG 99.03 trial. Median follow\u2010up was 11.3 years (range: 4.4\u201317.8). Lifetime direct health care costs, quality\u2010adjusted life\u2010years (QALYs) and incremental cost\u2010effectiveness ratios (ICERs) were calculated. Australian dollars AUD$50,000 was defined as the proposed willingness\u2010to\u2010pay threshold (WTP).<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>RT+R\u2010CVP was associated with an improvement of 0.711 QALYs compared to RT, 0.532 QALYs compared to RT+CVP, and was the dominant strategy. The costs of adverse events or retreatment for relapses or transformation had a minimal influence on the ICERs. Sensitivity analyses resulted in ICER values below the WTP with RT+R\u2010CVP remaining the dominant strategy.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>RT+R\u2010CVP is clearly cost\u2010effective and was the dominant strategy in early\u2010stage FL compared to RT or RT+CVP as it delivers superior outcomes at a lower cost from the Australian tax\u2010payer's perspective.<\/jats:p><\/jats:sec><jats:sec><jats:title>Trial Registration<\/jats:title><jats:p>The authors have confirmed clinical trial registration is not needed for this submission<\/jats:p><\/jats:sec>","DOI":"10.1002\/jha2.70002","type":"journal-article","created":{"date-parts":[[2025,2,12]],"date-time":"2025-02-12T10:10:11Z","timestamp":1739355011000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["An Economic Evaluation of the TROG 99.03 Trial: Systemic Therapy After Radiotherapy in Early\u2010Stage Follicular Lymphoma"],"prefix":"10.1002","volume":"6","author":[{"given":"Daniel","family":"Erku","sequence":"first","affiliation":[{"name":"Menzies Health Institute Queensland Griffith University  Gold Coast Queensland Australia"},{"name":"Mater Research Institute University of Queensland  Brisbane Queensland Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joshua W. D.","family":"Tobin","sequence":"additional","affiliation":[{"name":"Department of Haematology Princess Alexandra Hospital  Brisbane Queensland Australia"},{"name":"University of Queensland  Brisbane Queensland Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John F.","family":"Seymour","sequence":"additional","affiliation":[{"name":"Peter MacCallum Cancer Centre Royal Melbourne Hospital &amp; University of Melbourne  Melbourne Victoria Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael","family":"MacManus","sequence":"additional","affiliation":[{"name":"Peter MacCallum Cancer Centre Royal Melbourne Hospital &amp; University of Melbourne  Melbourne Victoria Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paul","family":"Scuffham","sequence":"additional","affiliation":[{"name":"Menzies Health Institute Queensland Griffith University  Gold Coast Queensland Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7980-8496","authenticated-orcid":false,"given":"Greg","family":"Hapgood","sequence":"additional","affiliation":[{"name":"Department of Haematology Princess Alexandra Hospital  Brisbane Queensland Australia"},{"name":"University of Queensland  Brisbane Queensland Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2025,2,12]]},"reference":[{"key":"e_1_2_8_2_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2013-03-491514"},{"key":"e_1_2_8_3_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2003-12-4434"},{"key":"e_1_2_8_4_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1996.14.4.1282"},{"key":"e_1_2_8_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0936-6555(89)80009-3"},{"key":"e_1_2_8_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijrobp.2005.08.010"},{"key":"e_1_2_8_7_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.25117"},{"key":"e_1_2_8_8_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.25149"},{"key":"e_1_2_8_9_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2011.40.6546"},{"key":"e_1_2_8_10_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.29491"},{"key":"e_1_2_8_11_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2004-08-3175"},{"key":"e_1_2_8_12_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2018.77.9892"},{"key":"e_1_2_8_13_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2018.79.3075"},{"key":"e_1_2_8_14_1","doi-asserted-by":"publisher","DOI":"10.1071\/AH17031"},{"key":"e_1_2_8_15_1","unstructured":"Australian Government Department of Health and Aged Care Pharmaceutical Benefits Scheme: Rituximab(2023).https:\/\/www.pbs.gov.au\/pbs\/search?term=rituximab."},{"key":"e_1_2_8_16_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2006.06.4618"},{"key":"e_1_2_8_17_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2007.13.5376"},{"key":"e_1_2_8_18_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijrobp.2007.09.051"},{"key":"e_1_2_8_19_1","unstructured":"Australian Bureau of Statistics Life Tables(2022).https:\/\/www.abs.gov.au\/statistics\/people\/population\/life\u2010tables\/2019\u20102021#data\u2010downloads."},{"key":"e_1_2_8_20_1","unstructured":"Australian Government Department of Health Australian Pharmaceutical Benefits Scheme http:\/\/www.pbs.gov.au\/pbs\/home."},{"key":"e_1_2_8_21_1","unstructured":"Australian Government Department of Health \u201cMBS Online: Medical Benefits Scheme \u201d last modified November 25 2024 http:\/\/www.mbsonline.gov.au."},{"key":"e_1_2_8_22_1","unstructured":"Independent Hospital Pricing Authority \u201cNational Efficient Price Determination 2018\u201319 Appendix H\u2014Price weights for Admitted Acute Patients\u2014AR\u2010DRG V9.0 Independent Hospital Pricing Authority \u201d2018.https:\/\/www.ihpa.gov.au\/publications\/national\u2010efficient\u2010price\u2010determination\u20102018\u201019."},{"key":"e_1_2_8_23_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.radonc.2011.05.013"},{"key":"e_1_2_8_24_1","unstructured":"\u201cQueensland Health Intranet QHEPS: Healthcare Funding and Costing \u201d2023."},{"key":"e_1_2_8_25_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.14990"},{"key":"e_1_2_8_26_1","doi-asserted-by":"publisher","DOI":"10.3310\/hta16370"},{"key":"e_1_2_8_27_1","doi-asserted-by":"publisher","DOI":"10.1080\/10428190701769665"},{"key":"e_1_2_8_28_1","unstructured":"Australian Government Department of Health \u201cGuidelines for Preparing a Submission to the Pharmaceutical Benefits Advisory Committee (Version 5.0) \u201d2016.https:\/\/pbac.pbs.gov.au\/content\/information\/files\/pbac\u2010guidelines\u2010version\u20105.pdf."},{"key":"e_1_2_8_29_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jval.2021.10.008"},{"key":"e_1_2_8_30_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0360-3016(01)01747-3"},{"key":"e_1_2_8_31_1","doi-asserted-by":"publisher","DOI":"10.1007\/BF02990087"},{"key":"e_1_2_8_32_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(14)70036-1"},{"key":"e_1_2_8_33_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0131158"},{"key":"e_1_2_8_34_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2019004588"},{"key":"e_1_2_8_35_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2018-04-843540"},{"key":"e_1_2_8_36_1","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2019000458"},{"key":"e_1_2_8_37_1","doi-asserted-by":"publisher","DOI":"10.1080\/10428194.2021.1957866"},{"key":"e_1_2_8_38_1","unstructured":"National Comprehensive Cancer Network \u201cClinical Practice Guidelines in Oncology: B\u2010Cell Lymphomas \u201d2023.https:\/\/www.nccn.org\/home."}],"container-title":["eJHaem"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/jha2.70002","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,12]],"date-time":"2025-03-12T06:33:52Z","timestamp":1741761232000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/jha2.70002"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2]]},"references-count":37,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,2]]}},"alternative-id":["10.1002\/jha2.70002"],"URL":"https:\/\/doi.org\/10.1002\/jha2.70002","archive":["Portico"],"relation":{},"ISSN":["2688-6146","2688-6146"],"issn-type":[{"value":"2688-6146","type":"print"},{"value":"2688-6146","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,2]]},"assertion":[{"value":"2024-08-21","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-01-16","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-02-12","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e70002"}}